CARDINAL HEALTH INC
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statemen
| Three Months Ended March 31, | Nine Months Ended March 31, | |||
|---|---|---|---|---|
| (in millions, except per common share amounts) | 2025 | 2024 | 2025 | 2024 |
| Revenue | $54,878 | $54,868 | $162,419 | $166,960 |
| Cost of products sold | 52,755 | 52,933 | 156,453 | 161,428 |
| Gross margin | 2,123 | 1,935 | 5,966 | 5,532 |
| Operating expenses: | ||||
| Distribution, selling, general and administrative expenses | 1,315 | 1,269 | 3,898 | 3,723 |
| Restructuring and employee severance | 28 | 53 | 61 | 106 |
| Amortization and other acquisition-related costs | 152 | 80 | 331 | 207 |
| Acquisition-related cash and share-based compensation costs | 20 | — | 20 | — |
| Impairments and (gain)/loss on disposal of assets, net | (17) | 84 | (15) | 626 |
| Litigation (recoveries)/charges, net | (105) | 80 | (176) | 28 |
| Operating earnings | 730 | 369 | 1,847 | 842 |
| Other (income)/expense, net | (9) | (1) | (11) | (10) |
| Interest expense, net | 74 | 28 | 141 | 42 |
| Earnings before income taxes | 665 | 342 | 1,717 | 810 |
| Provision for income taxes | 157 | 80 | 391 | 190 |
| Net earnings | 508 | 262 | 1,326 | 620 |
| Less: Net earnings attributable to noncontrolling interests | (2) | (1) | (4) | (3) |
| Net earnings attributable to Cardinal Health, Inc. | $506 | $261 | $1,322 | $617 |
| Earnings per common share attributable to Cardinal Health, Inc.: | ||||
| Basic | $2.11 | $1.07 | $5.47 | $2.51 |
| Diluted | 2.10 | 1.07 | 5.44 | 2.50 |
| Weighted-average number of common shares outstanding: | ||||
| Basic | 240 | 243 | 242 | 245 |
| Diluted | 241 | 245 | 243 | 247 |
| Cash dividends declared per common share | $0.5056 | $0.5006 | $1.5168 | $1.5018 |
| 21 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Financial Statements
Condensed Consolidated Statements of Comprehensive Income
| Three Months Ended March 31, | Nine Months Ended March 31, | |||
|---|---|---|---|---|
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| Net earnings | $508 | $262 | $1,326 | $620 |
| Other comprehensive income/(loss): | ||||
| Foreign currency translation adjustments and other | (2) | 1 | (13) | (4) |
| Net unrealized gain/(loss) on derivative instruments, net of tax | 6 | (6) | 4 | (5) |
| Total other comprehensive income/(loss), net of tax | 4 | (5) | (9) | (9) |
| Total comprehensive income | 512 | 257 | 1,317 | 611 |
| Less: comprehensive income attributable to noncontrolling interests | (2) | (1) | (4) | (3) |
| Total comprehensive income attributable to Cardinal Health, Inc. | $510 | $256 | $1,313 | $608 |
| 22 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Financial Statements
Condensed Consolidated Balance Sheets
| (in millions) | March 31, 2025 | June 30, 2024 |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and equivalents | $3,326 | $5,133 |
| Trade receivables, net | 12,666 | 12,084 |
| Inventories, net | 16,158 | 14,957 |
| Prepaid expenses and other | 2,398 | 2,663 |
| Assets held for sale | 47 | 47 |
| Total current assets | 34,595 | 34,884 |
| Property and equipment, net | 2,664 | 2,529 |
| Goodwill and other intangibles, net | 11,014 | 6,450 |
| Other assets | 1,598 | 1,258 |
| Total assets | $49,871 | $45,121 |
| Liabilities and Shareholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $32,812 | $31,759 |
| Current portion of long-term obligations and other short-term borrowings | 543 | 434 |
| Other accrued liabilities | 3,307 | 3,447 |
| Total current liabilities | 36,662 | 35,640 |
| Long-term obligations, less current portion | 7,136 | 4,658 |
| Deferred income taxes and other liabilities | 7,971 | 8,035 |
| Shareholders’ deficit: | ||
| Preferred shares, without par value: | ||
| Authorized—500 thousand shares, Issued—none | — | — |
| Common shares, without par value: | ||
| Authorized—755 million shares, Issued—271 million shares and 327 million shares at March 31, 2025 and June 30, 2024, respectively | 2,946 | 2,917 |
| Retained earnings/(accumulated deficit) | 664 | (286) |
| Common shares in treasury, at cost: 32 million shares and 83 million shares at March 31, 2025 and June 30, 2024, respectively | (6,382) | (5,677) |
| Accumulated other comprehensive loss | (176) | (167) |
| Total Cardinal Health, Inc. shareholders' deficit | (2,948) | (3,213) |
| Noncontrolling interests | 1,050 | 1 |
| Total shareholders’ deficit | (1,898) | (3,212) |
| Total liabilities and shareholders’ deficit | $49,871 | $45,121 |
| 23 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Financial Statements
Condensed Consolidated Statements of Shareholders' Deficit
| Common Shares · Retained Earnings/(Accumulated Deficit) · Treasury Shares · Accumulated OtherComprehensiveLoss · Noncontrolling Interests · TotalShareholders’ Deficit | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in millions) · Shares Issued · Amount · Shares · Amount | |||||||||||||||||
| Three Months Ended March 31, 2025 | |||||||||||||||||
| Balance at December 31, 2024 | 271 | $2,932 | $283 | (29) | $(6,026) | $(180) | $70 | $(2,921) | |||||||||
| Net earnings | 506 | 2 | 508 | ||||||||||||||
| Other comprehensive income, net of tax | 4 | 4 | |||||||||||||||
| Acquisitions | 963 | 963 | |||||||||||||||
| Vesting of noncontrolling units | 17 | 17 | |||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 13 | — | 22 | 35 | ||||||||||||
| Share repurchase program activity | — | (3) | (378) | (378) | |||||||||||||
| Dividends declared | (123) | (123) | |||||||||||||||
| Payments to noncontrolling interests | (3) | (3) | |||||||||||||||
| Other | — | 1 | (2) | 1 | — | ||||||||||||
| Balance at March 31, 2025 | 271 | $2,946 | $664 | (32) | $(6,382) | $(176) | $1,050 | $(1,898) | |||||||||
| Three Months Ended March 31, 2024 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at December 31, 2023 | 327 | $2,855 | $(535) | (83) | $(5,714) | $(155) | $2 | $(3,547) | ||||||
| Net earnings | 261 | 1 | 262 | |||||||||||
| Other comprehensive loss, net of tax | (5) | (5) | ||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 32 | — | 21 | 53 | |||||||||
| Dividends declared | (123) | (123) | ||||||||||||
| Other | 1 | — | 1 | |||||||||||
| Balance at March 31, 2024 | 327 | $2,887 | $(396) | (83) | $(5,693) | $(160) | $3 | $(3,359) | ||||||
| Nine Months Ended March 31, 2025 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at June 30, 2024 | 327 | $2,917 | $(286) | (83) | $(5,677) | $(167) | $1 | $(3,212) | |||||||||
| Net earnings | 1,322 | 4 | 1,326 | ||||||||||||||
| Other comprehensive loss, net of tax | (9) | (9) | |||||||||||||||
| Acquisitions | 1,035 | 1,035 | |||||||||||||||
| Vesting of noncontrolling units | 17 | 17 | |||||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 28 | 1 | 52 | 80 | ||||||||||||
| Share repurchase program activity | (6) | (757) | (757) | ||||||||||||||
| Retirement of treasury stock | (56) | — | 56 | — | — | ||||||||||||
| Dividends declared | (370) | (370) | |||||||||||||||
| Payments to noncontrolling interests | (7) | (7) | |||||||||||||||
| Other | — | 1 | (2) | — | (1) | ||||||||||||
| Balance at March 31, 2025 | 271 | $2,946 | $664 | (32) | $(6,382) | $(176) | $1,050 | $(1,898) | |||||||||
| Nine Months Ended March 31, 2024 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at June 30, 2023 | 327 | $2,746 | $(642) | (76) | $(4,911) | $(151) | $1 | $(2,957) | ||||||
| Net earnings | 617 | 3 | 620 | |||||||||||
| Other comprehensive loss, net of tax | (9) | (9) | ||||||||||||
| Employee stock plans activity, net of shares withheld for employee taxes | — | 41 | 1 | 77 | 118 | |||||||||
| Share repurchase program activity | — | 100 | (9) | (859) | (759) | |||||||||
| Dividends declared | (372) | (372) | ||||||||||||
| Other | 1 | 1 | (1) | — | ||||||||||
| Balance at March 31, 2024 | 327 | $2,887 | $(396) | (83) | $(5,693) | $(160) | $3 | $(3,359) | ||||||
| 24 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Financial Statements
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended March 31, | ||
|---|---|---|
| (in millions) | 2025 | 2024 |
| Cash flows from operating activities: | ||
| Net earnings | $1,326 | $620 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||
| Depreciation and amortization | 581 | 524 |
| Impairments and loss on sale of other investments | 2 | — |
| Impairments and (gain)/loss on disposal of assets, net | (15) | 626 |
| Share-based compensation | 91 | 88 |
| Provision for bad debts | 41 | 28 |
| Change in operating assets and liabilities, net of effects from acquisitions and divestitures: | ||
| Increase in trade receivables | (367) | (223) |
| Increase in inventories | (1,209) | (1,258) |
| Increase in accounts payable | 954 | 2,118 |
| Other accrued liabilities and operating items, net | (534) | (843) |
| Net cash provided by operating activities | 870 | 1,680 |
| Cash flows from investing activities: | ||
| Acquisition of subsidiaries, net of cash acquired | (3,855) | (1,192) |
| Proceeds from divestitures, net of cash sold | 2 | 9 |
| Additions to property and equipment | (315) | (318) |
| Proceeds from disposal of property and equipment | 3 | 10 |
| Purchases of investments | (6) | (3) |
| Proceeds from investments | 7 | 1 |
| Proceeds from net investment hedge terminations | 2 | 28 |
| Purchase of short-term time deposits | — | (550) |
| Proceeds from short-term investment in time deposit | 200 | — |
| Net cash used in investing activities | (3,962) | (2,015) |
| Cash flows from financing activities: | ||
| Proceeds from long-term obligations, net of issuance costs | 2,869 | 1,139 |
| Reduction of long-term obligations | (434) | (23) |
| Net tax proceeds/(withholding) from share-based compensation | (12) | 23 |
| Dividends on common shares | (374) | (377) |
| Purchase of treasury shares, net | (765) | (750) |
| Net cash provided by financing activities | 1,284 | 12 |
| Effect of exchange rate changes on cash and equivalents | 1 | (7) |
| Net decrease in cash and equivalents | (1,807) | (330) |
| Cash and equivalents at beginning of period | 5,133 | 4,076 |
| Cash and equivalents at end of period | $3,326 | $3,746 |
| 25 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Notes to Financial Statements
Notes to Condensed Consolidated Financial Statements
- Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.
Our fiscal year ends on June 30. References to fiscal 2025 and 2024 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2025 and June 30, 2024, respectively.
Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.
In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2025 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2025. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (our "2024 Form 10-K").
Revision of Prior Period Consolidated Financial Statements
As previously disclosed in the 2024 Form 10-K, we revised our prior period financial statements to correct for an accounting error related to the at-Home Solutions operating segment that was not material, individually or in the aggregate, to our previously issued Consolidated Financial Statements, as well as other unrelated immaterial errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. See Note 1 and Note 16 to the "Consolidated Financial Statements" in the 2024 Form 10-K for additional information.
Major Customers
On April 22, 2024, we announced that our pharmaceutical distribution contracts with OptumRx, which expired at the end of June 2024, would not be renewed. Sales to OptumRx generated 17 percent of our consolidated revenue in fiscal 2024.
Variable Interest Entities
We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements.
Consolidated Variable Interest Entities
We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, are considered the primary beneficiary of the VIE.
On January 1, 2020, GI Alliance ("GIA") entered into a management services arrangement with Texas Digestive Disease Consultants, PLLC (“TDDC”) that authorized GIA to perform certain management services in the manner that it deemed reasonably appropriate to meet the day-to-day business needs of TDDC. In exchange for the management services provided, GIA is entitled to receive an annual management fee equal to a percentage of TDDC’s net operating income. The agreement has a 15 year term with two successive 5 year terms set to renew automatically. Based on these determinations, we concluded that TDDC is a VIE and that GIA is the primary beneficiary.
The VIE does not have a material impact on our condensed consolidated statements of earnings or condensed consolidated statements of cash flows. Total assets and liabilities included in the consolidated balance sheets for the VIE were $524 million and $249 million, respectively, as of March 31, 2025.
| 26 | Cardinal Health | Q3 Fiscal 2025 Form 10-Q |
Notes to Financial Statements
Noncontrolling Interests
Noncontrolling interests represent the portion of net earnings, comprehensive income and net assets that is not attributable to Cardinal Health. Noncontrolling interests as of March 31, 2025 primarily represents third-party equity interests in GIA and ION. The net earnings attributable to noncontrolling interests in GIA contain certain call and put rights, however, the exercise of these options is fully within the control of Cardinal Health. and the associated noncontrolling interest has therefore been determined to be nonredeemable and classified within permanent equity. The fair value was estimated using the implied enterprise value based on the purchase price paid for the controlling interest. See Note 2, for additional information on the acquisition of GIA.
Recently Issued Financial Accounting Standards
and Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2024 Form 10-K.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. This guidance will be effective for us in our fiscal 2025 Form 10-K and the guidance must be applied retrospectively to all prior periods presented. We have evaluated the impact of adoption of this guidance on our disclosures and this will be reflected in our fiscal 2025 Form 10-K.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregated disclosures of certain categories of expenses which are included in any relevant income statement expense caption on an annual and interim basis. Additionally, the guidance requires the disclosure of total selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance
will be effective for us in fiscal 2028 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Recently Adopted Financial Accounting Standards
There were no new material accounting standards adopted during the nine months ended March 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.